Table 1.

Sample Usage and Clinical Data

Participant	A		B		C		D		E	F		G
CSF collection time point	Early	Late	Early	Late	Early	Late	Early	Late	Early	Early	Late	Late
Flow	+	+	+	+	+	+	+	+	—	—	—	—
scRNA	—	—	—	—	+	+	+	+	+	+	+	+
Clinical presentation	Headaches, communicating hydrocephalus		Communicating hydrocephalus, meningitis		Obstructive hydrocephalus, meningitis		Difficulty walking, spinal cord compression		Seizures	Ischemic stroke		Headaches, communicating hydrocephalus
New diagnosis vs. recurrence	New Diagnosis		Recurrence		Reccurence		Recurrence		New Diagnosis	Recurrence		Recurrence
On albendazole and/or praziquantel	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes
Time on anthelmintics (mo)	<1	4	—	3	1	6	—	60	—	—	3	8
Dexamethasone equivalent (mg)	7.5	9	0	0.9	1.5	0.8	0	0	18	1.1	4	0.8
Steroid-sparing agents	—	—	—	—	—	Etanercept	Methotrexate	—	—	—	Etanercept, methotrexate	—
T. solium qPCR (Cq)	19.6	25.6	32.8	28.2	22.1	24.2	35.8	29	40	33.2	27.1	34.3
Taenia antigena (ng/mL)	17,104	8,207	>4,000	20	2,239	47	6,580	527	21	10	0	0

(—) Indicated field not applicable.

^aCapture ELISA TsG10, commercial ELISA, or B60/158 Luminex assay.